Fidson picked to make generic flu drug under MPP licence, joining global manufacturers

Fidson Healthcare Plc has been selected as a sublicence manufacturer to develop and produce a generic version of Roche’s influenza medicine baloxavir marboxil, the company will supply as part of a wider effort to diversify manufacturing capacity and strengthen pandemic preparedness.

The move comes under a voluntary licence managed by the Medicines Patent Pool (MPP) that allows multiple manufacturers to develop generic versions of the antiviral. Reports say Fidson joins other manufacturers across several countries that were also granted sublicences.

Why it matters

Expanding the number of manufacturers able to produce baloxavir aims to increase global supply options for the antiviral and to reduce reliance on a small number of producers. Proponents of the MPP model say sublicences can help boost production capacity and improve access to important treatments during seasonal outbreaks or future pandemics.

Scope and partners

Reports indicate the group of sublicensees includes manufacturers in Brazil, China and India; another account lists additional countries that have firms participating, naming Indonesia, Malaysia, Uganda, Ukraine and Vietnam. One report describes Fidson as one of eleven selected manufacturers; another says production under the sublicence will support supply to 129 countries.

What has been confirmed

• Fidson was named a sublicence manufacturer for a generic of Roche’s baloxavir marboxil under the MPP voluntary licence.
• The selection places Fidson among a group of manufacturers across multiple countries pursuing production of the same drug to diversify global manufacturing capacity.

Details still to clarify

Available reporting does not provide a full list of sublicensees agreed by the MPP or specify timelines for regulatory approvals, manufacturing start dates, pricing, or which countries Fidson will be authorized to supply. The different accounts also vary on the exact number of sublicensees and the number of countries covered by the sublicence arrangements.

Context for Nigeria

Fidson is a leading pharmaceutical manufacturer in Nigeria. Its selection for a role in global production of an antiviral medicine reflects broader efforts to involve manufacturers in low- and middle-income countries in production of key health technologies, which advocates say could strengthen regional preparedness and access.

Next steps

Further details are expected as MPP and the sublicensees publish formal announcements or regulatory filings. Those updates should clarify manufacturing timelines, the extent of geographic supply rights, and arrangements for quality assurance and distribution.